Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin around atrial fibrillation ablation
ACTRN12621000685819Phase 2Not yet recruiting
- Sponsor
- Flinders University
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dapagliflozin in Atrial fibrillation (AFib), sponsored by Flinders University. Primary endpoints: Atrial fibrillation burden, Change in electrophysiologic rate constants and 1 more. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ACTRN12621000685819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000685819.